Fasoracetam (NS-105) | CAS 110958-19-5 | mGlu Receptor Modulator (Research Use Only) | Knowlux

Product Description

Fasoracetam, CAS 110958-19-5, is a synthetic racetam-family compound supplied by Knowlux for laboratory research use. It is also known as NS-105 or NFC-1. The molecular formula is C10H16N2O2 and the molecular weight is 196.25 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Regulatory status clarification: Fasoracetam is not approved by the FDA for any indication. It has received an FDA Orphan Drug Designation for the treatment of 22q11.2 deletion syndrome (designated October 2024), but this designation does not constitute approval, and the sponsor (Nobias Therapeutics) has not received marketing authorization. Clinical development status is reported as inactive. Commercial listings frequently describe fasoracetam as a nootropic or cognitive enhancer; those designations attach to unregulated supplement markets and do not apply to, and are not represented by, this research-grade lot.

Product Parameters

Product Details

1. Overview

Fasoracetam is a member of the racetam family, structurally distinct from piracetam and aniracetam in its receptor pharmacology. Unlike classic racetams that primarily modulate AMPA receptors, fasoracetam has been characterised as a non-selective metabotropic glutamate receptor (mGluR) activator with additional interactions at GABA(B) receptors and neuronal acetylcholine receptors. It has been investigated in clinical research for ADHD in individuals with genetic disorders affecting mGluR networks, and more recently for neuropsychiatric symptoms in 22q11.2 deletion syndrome. Knowlux supplies fasoracetam as a research-grade material for laboratory and analytical use; this supply is not intended for human administration and does not constitute a finished drug or supplement product.

2. Mechanism of Action (Research Context)

Published research describes fasoracetam as a compound that interacts with multiple neurotransmitter systems. The most consistently reported mechanism is activation of metabotropic glutamate receptors (mGluR II and III subtypes), which function as autoreceptors that inhibit excessive glutamate release when activated. This modulation is theorised to restore glutamate homeostasis and reduce excitotoxicity without sedation. Fasoracetam has also been reported to upregulate muscarinic and nicotinic acetylcholine receptors, potentially enhancing cholinergic signalling efficiency. NCATS Inxight Drugs additionally notes interactions with GABA(B) receptors. A Phase II randomized crossover trial in children with 22q11.2 deletion syndrome (n=34) reported that fasoracetam 200 mg twice daily was safe and well-tolerated over 6 weeks, with a CGI-I improvement that approached but did not reach statistical significance (p=0.0672). These descriptions are derived from published research and are provided for scientific reference only. Knowlux makes no claims regarding the efficacy, safety, or suitability of this product for any human application. Promotion of fasoracetam for memory enhancement, ADHD treatment, anxiety reduction, or any health benefit is not supported by Knowlux and is inconsistent with research-use-only supply.

3. Quality Control

4. Applications

• Reference standard for fasoracetam analytical method development

• In vitro mGluR binding and functional assay development

• Glutamatergic and cholinergic neurotransmission research models

• Comparative studies of racetam-family compounds with distinct receptor profiles

• LC-MS and biochemical assay calibrators

5. Packaging, Storage & Shipping

Powder: amber glass vial or high-barrier foil bag under nitrogen headspace, sealed with tamper-evident closure. Secondary packing: light-protected carton with desiccant. Ambient or cold-chain shipping with temperature logger where required. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, heavy metal statement. Specification summaries and audit support available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Fasoracetam is not FDA-approved for any indication; the FDA Orphan Drug Designation for 22q11.2 deletion syndrome (October 2024) does not constitute marketing approval, and clinical development is reported as inactive. Fasoracetam is not a permitted dietary-supplement ingredient. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.